Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Somatropin may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
Genotropin is a recombinant human growth hormone (also called somatropin). It has the same structure as natural human growth hormone which is needed for bones and muscles to grow. It also helps your fat and muscle tissues to develop in the right amounts. It is recombinant meaning it is not made from human or animal tissue. In children, Genotropin is used to treat the following growth disturbances:
Page 1 of 22
2.
e Genotropin
Do not use Genotropin and tell your doctor if
• •
•
• •
•
Children with chronic renal (kidney) insufficiency: Your doctor should examine your kidney function and your growth rate before starting Genotropin. Medical treatment for your kidney condition should be continued. Genotropin treatment should be stopped at kidney transplantation. Children with Prader-Willi syndrome: Your doctor will give you diet restrictions to follow to control your weight. Your doctor will assess you for signs of upper airway obstruction, sleep apnoea (where your breathing is interrupted during sleep), or respiratory infection before you start treatment with Genotropin. During treatment, if you show signs of upper airway obstruction (including starting to snore or worsening of snoring), your doctor will need to examine you and may interrupt your treatment with Genotropin. During treatment, your doctor will check you for signs of scoliosis, a type of spinal deformity. During treatment, if you develop a lung infection, tell your doctor so that he can treat the infection. Children born small or too light at birth: If you were small or too light at birth and are aged between 9 and 12 years, ask your doctor for specific advice relating to puberty and treatment with this product.
Page 2 of 22
• •
Your doctor will check your blood sugar and insulin levels before the start of treatment and every year during treatment. Treatment should be continued until you have stopped growing.
Using other medicines Tell your doctor or pharmacist if you are using or have recently used any other medicines, including medicines obtained without a prescription. Warnings and precautions Talk to your doctor or pharmacist before using Genotropin. If you have a replacement therapy with glucocorticoids, you should consult your doctor regularly, as you may need adjustment of your glucocorticoid dose. You should tell your doctor if you are using:
3.
Genotropin
Recommended dosage The dose depends on your size, the condition for which you are being treated and how well growth hormone works for you. Everyone is different. Your doctor will advise you about your individualised dose of Genotropin in milligrams (mg) from either your body weight in kilograms (kg) or your body surface area calculated from your height and weight in square metres (m2), as well as your treatment schedule. Do not change the dosage and treatment schedule without consulting your doctor. Children with growth hormone deficiency: 0.025-0.035 mg/kg body weight per day or 0.7-1.0 mg/m2 body surface area per day. Higher doses can be used. When growth hormone deficiency continues into adolescence, Genotropin should be continued until completion of physical development. Children with Turner syndrome: 0.045-0.050 mg/kg body weight per day or 1.4 mg/m2 body surface area per day. Children with chronic renal (kidney) insufficiency: 0.045-0.050 mg/kg body weight per day or 1.4 mg/m2 body surface area per day. Higher doses may be necessary if the rate of growth is too low. Dosage adjustment may be necessary after 6 months of treatment. Page 3 of 22
Children with Prader-Willi syndrome: 0.035 mg/kg body weight per day or 1.0 mg/m2 body surface area per day. The daily dosage should not exceed 2.7 mg. Treatment should not be used in children who have almost stopped growing after puberty. Children born smaller or lighter than expected and with growth disturbance: 0.035 mg/kg body weight per day or 1.0 mg/m2 body surface area per day. It is important to continue treatment until final height is reached. Treatment should be discontinued after the first year if you are not responding or if you have reached your final height and stopped growing. Adults with growth hormone deficiency: If you continue Genotropin after treatment during childhood you should start with 0.2-0.5 mg per day. This dosage should be gradually increased or decreased according to blood test results as well as clinical response and side effects. If your growth hormone deficiency starts during adult life you should start with 0.15-0.3 mg per day. This dosage should be gradually increased according to blood test results as well as clinical response and side effects. The daily maintenance dose seldom exceeds 1.0 mg per day. Women may require higher doses than men. Dosage should be monitored every 6 months. Persons above 60 years should start with a dose of 0.1-0.2 mg per day which should be slowly increased according to individual requirements. The minimum effective dose should be used. The maintenance dose seldom exceeds 0.5 mg per day. Follow the instructions given to you by your doctor. Injecting Genotropin Genotropin is intended for subcutaneous use. This means that it is injected through a short injection needle into the fatty tissue just under your skin. Your doctor should have already shown you how to use Genotropin. Always inject Genotropin exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure. The instructions for using the GoQuick® pre-filled pen are provided in the carton with the prefilled pen. The instructions for using the Genotropin two-chamber cartridge with the Genotropin Pen are provided with your device. Refer to the instuctions for use before using your medicine. When using a pre-filled pen or a pen injection device, the needle must be screwed on before mixing. A new needle must be used for each injection. Needles must not be re-used.
4.
Like all medicines, Genotropin can cause side effects, although not everybody gets them. The very common and common side effects in adults may start within the first months of treatment and may either stop spontaneously or if your dose is reduced. Very common side effects (may affect more than 1 in 10 people) include: In adults:
•
• • • • • • • •
Leukaemia (This has been reported in a small number of growth hormone deficiency patients, some of whom have been treated with somatropin. However, there is no evidence that leukaemia incidence is increased in growth hormone recipients without predisposing factors). Increased intracranial pressure (which causes symptoms such as strong headache, visual disturbances or vomiting). Numbness/tingling. Rash. Itching. Raised itchy bumps on the skin. Muscle pain. Breast enlargement (gynaecomastia). Water retention (which shows as puffy fingers or swollen ankles, for a short time at the start of treatment).
In adults:
Page 6 of 22
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
5.
Genotropin
Keep out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton as MM/YYYY. The expiry date refers to the last day of that month. Before reconstitution Store in a refrigerator (2C – 8C). Keep the two-chamber cartridge in the outer carton in order to protect from light. Before opening, the product may be taken out of the refrigerator, without being replaced, for a maximum period of 1 month at a temperature not above 25°C but after this it must be discarded. After reconstitution Store in a refrigerator (2C – 8C) for up to 28 days. Do not freeze. Keep the GoQuick pre-filled pen in the GoQuick outer carton, or the two-chamber cartridge in the Pen box in order to protect from light. Do not use this medicine if you notice particles or if the solution is cloudy. Do not freeze or expose Genotropin to frost. If it freezes, do not use it. Never throw away needles or partly used or empty cartridges with your ordinary rubbish. When you have finished with a needle, you must discard it carefully in a suitable sharps container so that no-one will be able to use it or prick themselves on it. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6.
What Genotropin contains
Page 7 of 22
Marketing Authorisation Holder Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom Manufacturer Pfizer Manufacturing Belgium NV Rijksweg 12 2870 Puurs-Sint-Amands Belgium This medicine is authorised in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names: Genotropin: Austria, Denmark, Finland, Germany, Greece, Ireland, Italy, Netherlands, Portugal, Sweden, United Kingdom (Northern Ireland) Genotonorm: Belgium, France, Luxembourg Genotonorm Kabipen: Spain This leaflet was last approved in: 11/2023 Ref: 41_0
Page 8 of 22
GENOTROPIN GOQUICK® INSTRUCTIONS FOR USE Please read these instructions completely before using your GoQuick Pen. If you have any questions about your dose or your treatment with Genotropin, call your doctor or nurse. About GoQuick GoQuick is a pre-filled, multidose, disposable injection pen that holds 5.3 mg of somatropin. Your pen can deliver doses from 0.1 mg to 1.5 mg of Genotropin. Each click of the black ring changes the dose by 0.05 mg. The Genotropin in your pen is mixed only once, when you start a new pen. You never have to change cartridges. When your pen is empty, you just start a new pen. Your pen has dose memory. The dose is set once on a new pen. Your pen then allows you to draw up the same set dose for each injection. This will prevent you from drawing more than your set dose. Important Information
Pen needles are not included with your GoQuick Pen. You will need to get pen needles up to a length of 8 mm from your pharmacy.
o o
31G or 32G (Novo Nordisk®) 32.5G or 34G (Terumo)
Setting up and using a new GoQuick Pen Step 1
• •
•
Wash and dry your hands. Gather the following supplies on a clean flat surface: o A new GoQuick Pen o A new needle (not included) o Suitable sharps container (not included). Check the expiry date on your pen label. Do not use your pen if the pen has passed its expiry date.
Step 2
• •
•
Choose Injection Site
Choose and clean an injection site as recommended by your doctor or nurse. Choose a different site each time you give yourself an injection. Each new injection should be given at least 2 cm from the site you used before. Avoid areas that are bony, bruised, red, sore or hard, and areas of the skin that have scars or skin conditions.
Step 3
• • •
Preparation
Attach New Needle
Pull the white cap straight off your pen. Take a new needle and peel off the paper seal. Gently push and then screw the needle onto your pen. Do not overtighten. Note: Be careful not to attach the needle at an angle. This may cause your pen to leak. Leave both needle covers on the needle.
Page 10 of 22
Step 4
• • • •
Hold your pen with the needle-end pointing up and the "A" facing you. Firmly twist the cartridge holder into the pen until "B" clicks into the notch. Gently tilt your pen from side to side to help dissolve the powder completely. Do not shake. Shaking can damage the growth hormone. Check that the liquid in the cartridge is clear and all the powder is dissolved. o If the liquid is cloudy or you see any powder, gently tilt your pen from side to side a few more times. o If the liquid is still cloudy or you see any powder, do not use the pen and try again with a new pen.
Step 5
• • • • •
Mix the Genotropin
Remove the Air from Your Pen
Pull the outer needle cover off. Keep it to remove the needle after your injection. Leave the inner needle cover on. Note: You should see an inner needle cover after you have removed the outer cover. If you do not see this, try to attach the needle again. Hold your pen with the needle-end pointing up. Gently tap the cartridge holder to help any trapped air move to the top. Firmly twist the cartridge holder into your pen until "C" clicks into the notch. o Some liquid may appear around the inner needle cover. This is normal.
Step 6
Prime Your Pen
Priming removes any remaining air by pushing a small amount of liquid out of your pen. The priming dose is 0.1 mg and is different from the dose your doctor or nurse has prescribed. Only prime your pen the first time you use it.
• • •
Hold your pen with the needle pointing straight up. Push the blue injection button all the way in. Check for liquid at the needle tip. If liquid appears, your pen is primed. o If liquid does not appear, repeat the priming steps up to two additional times. o If liquid still does not appear, do not use your pen. Contact your doctor or nurse for advice.
Step 7
Set and Draw Up Your Dose
The first time you use your pen you will set the dose that your doctor or nurse has prescribed. You do not need to set the dose again until you start a new pen or your doctor or nurse tells you.
Check Your Dose
Your dose on the black rod should line up with the white pointer.
• • •
Give Your Injection of Genotropin
Hold your pen over the injection site. Insert the needle straight into the skin. Push the blue injection button down until it stops clicking.
Page 12 of 22
• •
Wait for a full 5 seconds to ensure that your complete dose is injected. Keep lightly pressing on the blue injection button while you count. After 5 seconds, pull the needle straight out of your skin. Note: If you see a drop of liquid at the injection site or needle tip, then with your next injection try pressing the blue injection button for longer before pulling the needle out of your skin.
Step 10
• • • • •
Remove Needle
Carefully cover the needle with the outer needle cover. Caution: Do not touch the needle to avoid a needle stick. Use the needle cover to unscrew the needle. Throw away (dispose of) the needle in a suitable sharps container. Push the white cap onto your pen. Store your pen in the refrigerator until your next injection.
Routine (daily) use of GoQuick Pen Step 1
• •
•
Preparation
Wash and dry your hands. Gather the following supplies on a clean flat surface: o An already mixed GoQuick Pen o A new needle (not included) o Suitable sharps container (not included). Check the expiry date on your pen label. Do not use your pen if the pen has passed its expiry date. Do not use your pen 28 days after first use.
Step 2
Choose Injection Site
Page 13 of 22
• •
Choose and clean an injection site as recommended by your doctor or nurse. Choose a different site each time you give yourself an injection. Each new injection should be given at least 2 cm from the site you used before. Avoid areas that are bony, bruised, red, sore or hard, and areas of the skin that have scars or skin conditions.
Step 3
• • • •
Attach New Needle
Pull the white cap straight off your pen. Take a new needle and peel off the paper seal. Gently push and then screw the needle onto your pen. Do not overtighten. Note: Be careful not to attach the needle at an angle. This may cause your pen to leak. Remove both needle covers. o Keep the outer needle cover to remove the needle after your injection.
Step 4
Draw Up Your Dose
• • •
Turn the grey dial in the direction of the arrows until it stops clicking. Your dose on the black rod should line up with the white pointer. Check that the dose you drew up on the black rod is the same as the dose you set in the memory window. o If the doses match, your pen is ready to give your injection. Note: If the dose you drew up is smaller, your pen does not have a full dose of Genotropin. Follow what your doctor or nurse told you to do when your pen does not have a full dose . Or contact your doctor or nurse for advice. Step 5
• • • •
Give Your Injection of Genotropin
Hold your pen over the injection site. Insert the needle straight into the skin. Push the blue injection button down until it stops clicking. Wait for a full 5 seconds to ensure that your complete dose is injected. Keep lightly pressing on the blue injection button while you count.
Page 14 of 22
•
After 5 seconds, pull the needle straight out of your skin. Note: If you see a drop of liquid at the injection site or needle tip, then with your next injection try pressing the blue injection button for longer before pulling the needle out of your skin.
Step 6
• • • • •
Remove Needle
Carefully cover the needle with the outer needle cover. Caution: Do not touch the needle to avoid a needle stick. Use the needle cover to unscrew the needle. Throw away (dispose of) the needle in a suitable sharps container. Push the white cap onto your pen. Store your pen in the refrigerator until your next injection.
Using the Needle Guard (Optional) The needle guard is an optional feature supplied separately to hide the needle during injection. Attach the needle guard: Attach the needle guard after Step 5 (Setting up and using a new GoQuick Pen) to avoid a needle stick.
Page 15 of 22
GENOTROPIN GOQUICK® INSTRUCTIONS FOR USE Please read these instructions completely before using your GoQuick Pen. If you have any questions about your dose or your treatment with Genotropin, call your doctor or nurse. About GoQuick GoQuick is a pre-filled, multidose, disposable injection pen that holds 12 mg of somatropin. Your pen can deliver doses from 0.3 mg to 4.5 mg of Genotropin. Each click of the black ring changes the dose by 0.15 mg. The Genotropin in your pen is mixed only once, when you start a new pen. You never have to change cartridges. When your pen is empty, you just start a new pen. Your pen has dose memory. The dose is set once on a new pen. Your pen then allows you to draw up the same set dose for each injection. This will prevent you from drawing more than your set dose. Important Information
Pen needles are not included with your GoQuick Pen. You will need to get pen needles up to a length of 8 mm from your pharmacy.
o o
31G or 32G (Novo Nordisk®) 32.5G or 34G (Terumo)
Setting up and using a new GoQuick Pen Step 1
• •
•
Wash and dry your hands. Gather the following supplies on a clean flat surface: o A new GoQuick Pen o A new needle (not included) o Suitable sharps container (not included). Check the expiry date on your pen label. Do not use your pen if the pen has passed its expiry date.
Step 2
• •
•
Choose Injection Site
Choose and clean an injection site as recommended by your doctor or nurse. Choose a different site each time you give yourself an injection. Each new injection should be given at least 2 cm from the site you used before. Avoid areas that are bony, bruised, red, sore or hard, and areas of the skin that have scars or skin conditions.
Step 3
• • •
Preparation
Attach New Needle
Pull the white cap straight off your pen. Take a new needle and peel off the paper seal. Gently push and then screw the needle onto your pen. Do not overtighten. Note: Be careful not to attach the needle at an angle. This may cause your pen to leak. Leave both needle covers on the needle.
Page 17 of 22
Step 4
• • • •
Hold your pen with the needle-end pointing up and the "A" facing you. Firmly twist the cartridge holder into your pen until "B" clicks into the notch. Gently tilt your pen from side to side to help dissolve the powder completely. Do not shake. Shaking can damage the growth hormone. Check that the liquid in the cartridge is clear and all the powder is dissolved. o If the liquid is cloudy or you see any powder, gently tilt your pen from side to side a few more times. o If the liquid is still cloudy or you see any powder, do not use the pen and try again with a new pen.
Step 5
• • • • •
Mix the Genotropin
Remove the Air from Your Pen
Pull the outer needle cover off. Keep it to remove the needle after your injection. Leave the inner needle cover on. Note: You should see an inner needle cover after you have removed the outer cover. If you do not see this, try to attach the needle again. Hold your pen with the needle-end pointing up. Gently tap the cartridge holder to help any trapped air move to the top. Firmly twist the cartridge holder into your pen until "C" clicks into the notch. o Some liquid may appear around the inner needle cover. This is normal.
Step 6
Prime Your Pen
Priming removes any remaining air by pushing a small amount of liquid out of your pen. The priming dose is 0.3 mg and is different from the dose your doctor or nurse has prescribed. Only prime your pen the first time you use it.
• • •
Hold your pen with the needle pointing straight up. Push the purple injection button all the way in. Check for liquid at the needle tip. If liquid appears, your pen is primed. o If liquid does not appear, repeat the priming steps up to two additional times. o If liquid still does not appear, do not use your pen. Contact your doctor or nurse for advice.
Step 7
Set and Draw Up Your Dose
The first time you use your pen you will set the dose that your doctor or nurse has prescribed. You do not need to set the dose again until you start a new pen or your doctor or nurse tells you.
Check Your Dose
Your dose on the black rod should line up with the white pointer.
• • •
Give Your Injection of Genotropin
Hold your pen over the injection site. Insert the needle straight into the skin. Push the purple injection button down until it stops clicking. Page 19 of 22
• •
Wait for a full 5 seconds to ensure that your complete dose is injected. Keep lightly pressing on the purple injection button while you count. After 5 seconds, pull the needle straight out of your skin. Note: If you see a drop of liquid at the injection site or needle tip, then with your next injection try pressing the purple injection button for longer before pulling the needle out of your skin.
Step 10
• • • • •
Remove Needle
Carefully cover the needle with the outer needle cover. Caution: Do not touch the needle to avoid a needle stick. Use the needle cover to unscrew the needle. Throw away (dispose of) the needle in a suitable sharps container. Push the white cap onto your pen. Store your pen in the refrigerator until your next injection.
Routine (daily) use of GoQuick Pen Step 1
• •
•
Preparation
Wash and dry your hands. Gather the following supplies on a clean flat surface: o An already mixed GoQuick Pen o A new needle (not included) o Suitable sharps container (not included). Check the expiry date on your pen label. Do not use your pen if the pen has passed its expiry date. Do not use your pen 28 days after first use.
Step 2
Choose Injection Site
Page 20 of 22
• •
Choose and clean an injection site as recommended by your doctor or nurse. Choose a different site each time you give yourself an injection. Each new injection should be given at least 2 cm from the site you used before. Avoid areas that are bony, bruised, red, sore or hard, and areas of the skin that have scars or skin conditions.
Step 3
Attach New Needle
Pull the white cap straight off your pen.
Draw Up Your Dose
• • •
Turn the grey dial in the direction of the arrows until it stops clicking. Your dose on the black rod should line up with the white pointer. Check that the dose you drew up on the black rod is the same as the dose you set in the memory window. o If the doses match, your pen is ready to give your injection. Note: If the dose you drew up is smaller, your pen does not have a full dose of Genotropin. Follow what your doctor or nurse told you to do when your pen does not have a full dose. Or contact your doctor or nurse for advice. Step 5
• • • •
Give Your Injection of Genotropin
Hold your pen over the injection site. Insert the needle straight into the skin. Push the purple injection button down until it stops clicking. Wait for a full 5 seconds to ensure that your complete dose is injected. Keep lightly pressing on the purple injection button while you count. Page 21 of 22
•
After 5 seconds, pull the needle straight out of your skin. Note: If you see a drop of liquid at the injection site or needle tip, then with your next injection try pressing the purple injection button for longer before pulling the needle out of your skin.
Step 6
• • • • •
Remove Needle
Carefully cover the needle with the outer needle cover. Caution: Do not touch the needle to avoid a needle stick. Use the needle cover to unscrew the needle. Throw away (dispose of) the needle in a suitable sharps container. Push the white cap onto your pen. Store your pen in the refrigerator until your next injection.
Using the Needle Guard (Optional) The needle guard is an optional feature supplied separately to hide the needle during injection. Attach the needle guard: Attach the needle guard after Step 5 (Setting up and using a new GoQuick Pen) to avoid a needle stick.
Page 22 of 22
Genotropin 5.3mg powder and solvent for solution for injection comes as injection containing 5.3mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Genotropin 5.3mg powder and solvent for solution for injection is somatropin.
This leaflet reproduces the patient information leaflet approved for Genotropin 5.3mg powder and solvent for solution for injection, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Children
Growth disturbance due to insufficient secretion of growth hormone (growth hormone deficiency, GHD) and growth disturbance associated with Turner syndrome or chronic renal insufficiency.
Growth disturbance [current height standard deviation score (SDS) < - 2.5 and parental adjusted height SDS < - 1] in short children born small for gestational age (SGA), with a birth weight and/or length below - 2 SD, who failed to show catch-up growth [height velocity (HV) SDS <0 during the last year] by 4 years of age or later.
Prader-Willi syndrome (PWS), for improvement of growth and body composition. The diagnosis of PWS should be confirmed by appropriate genetic testing.
Adults
Replacement therapy in adults with pronounced growth hormone deficiency.
Adult Onset: Patients who have severe growth hormone deficiency associated with multiple hormone deficiencies as a result of known hypothalamic or pituitary pathology, and who have at least one known deficiency of a pituitary hormone not being prolactin. These patients should undergo an appropriate dynamic test in order to diagnose or exclude a growth hormone deficiency.
Childhood Onset: Patients who were growth hormone deficient during childhood as a result of congenital, genetic, acquired, or idiopathic causes. Patients with childhood onset GHD should be re-evaluated for growth hormone secretory capacity after completion of longitudinal growth. In patients with a high likelihood for persistent GHD, i.e. a congenital cause or GHD secondary to a pituitary/hypothalamic disease or insult, an insulin-like growth factor-I (IGF-I) SDS < - 2 off growth hormone treatment for at least 4 weeks should be considered sufficient evidence of profound GHD.
All other patients will require IGF-I assay and one growth hormone stimulation test.
The dosage and administration schedule should be individualized.
The injection should be given subcutaneously and the site varied to prevent lipoatrophy.
Growth disturbance due to insufficient secretion of growth hormone in children: Generally a dose of 0.025 - 0.035 mg/kg body weight per day or 0.7 - 1.0 mg/m2 body surface area per day is recommended. Even higher doses have been used.
Where childhood onset GHD persists into adolescence, treatment should be continued to achieve full somatic development (e.g. body composition, bone mass). For monitoring, the attainment of a normal peak bone mass defined as a T score > - 1 (i.e. standardized to average adult peak bone mass measured by dual energy X-ray absorptiometry taking into account sex and ethnicity) is one of the therapeutic objectives during the transition period. For guidance on dosing see adult section below.
Prader-Willi syndrome, for improvement of growth and body composition in children: Generally a dose of 0.035 mg/kg body weight per day or 1.0 mg/m2 body surface area per day is recommended. Daily doses of 2.7 mg should not be exceeded. Treatment should not be used in children with a growth velocity of less than 1 cm per year and near closure of epiphyses.
Growth disturbance due to Turner syndrome: A dose of 0.045 - 0.050 mg/kg body weight per day or 1.4 mg/m2 body surface area per day is recommended.
Growth disturbance in chronic renal insufficiency: A dose of 0.045 - 0.050 mg/kg body weight per day (1.4 mg/m2 body surface area per day) is recommended. Higher doses can be needed if growth velocity is too low. A dose correction can be needed after six months of treatment.
Growth disturbance in short children born small for gestational age: A dose of 0.035 mg/kg body weight per day (1 mg/m2 body surface area per day) is usually recommended until final height is reached (see section 5.1). Treatment should be discontinued after the first year of treatment if the height velocity SDS is below + 1. Treatment should be discontinued if height velocity is <2 cm/year and, if confirmation is required, bone age is >14 years (girls) or >16 years (boys), corresponding to closure of the epiphyseal growth plates.
Dosage recommendations in Pediatric Patients
Indication
mg/kg body weight
dose per day
mg/m2 body surface area
dose per day
Growth hormone deficiency in children
0.025 - 0.035
0.7 - 1.0
Prader-Willi syndrome in children
0.035
1.0
Turner syndrome
0.045 - 0.050
1.4
Chronic renal insufficiency
0.045 - 0.050
1.4
Children born small for gestational age
0.035
1.0
Growth hormone deficient adult patients: In patients who continue growth hormone therapy after childhood GHD, the recommended dose to restart is 0.2 – 0.5 mg per day. The dose should be gradually increased or decreased according to individual patient requirements as determined by the IGF-I concentration.
In patients with adult-onset GHD, therapy should start with a low dose, 0.15 – 0.3 mg per day. The dose should be gradually increased according to individual patient requirements as determined by the IGF-I concentration.
In both cases treatment goal should be IGF-I concentrations within 2 SDS from the age corrected mean. Patients with normal IGF-I concentrations at the start of the treatment should be administered growth hormone up to an IGF-I level into upper range of normal, not exceeding the 2 SDS. Clinical response and side effects may also be used as guidance for dose titration. It is recognised that there are patients with GHD who do not normalize IGF-I levels despite a good clinical response, and thus do not require dose escalation. The maintenance dose seldom exceeds 1.0 mg per day. Women may require higher doses than men, with men showing an increasing IGF-I sensitivity over time. This means that there is a risk that women, especially those on oral oestrogen replacement are under-treated while men are over-treated. The accuracy of the growth hormone dose should therefore be controlled every 6 months. As normal physiological growth hormone production decreases with age, dose requirements are reduced. In patients above 60 years, therapy should start with a dose of 0.1 - 0.2 mg per day and should be slowly increased according to individual patient requirements. The minimum effective dose should be used. The maintenance dose in these patients seldom exceeds 0.5 mg per day.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Somatropin must not be used when there is any evidence of activity of a tumour. Intracranial tumours must be inactive and antitumour therapy must be completed prior to starting growth hormone therapy. Treatment should be discontinued if there is evidence of tumour growth.
GENOTROPIN should not be used for growth promotion in children with closed epiphyses.
Patients with acute critical illness suffering complications following open heart surgery, abdominal surgery, multiple accidental trauma, acute respiratory failure or similar conditions should not be treated with GENOTROPIN (regarding patients undergoing substitution therapy, see section 4.4).
Diagnosis and therapy with GENOTROPIN should be initiated and monitored by physicians who are appropriately qualified and experienced in the diagnosis and management of patients with the therapeutic indication of use.
Myositis is a very rare adverse event that may be related to the preservative metacresol. In the case of myalgia or disproportionate pain at injection site, myositis should be considered and if confirmed, a GENOTROPIN presentation without metacresol should be used.
The maximum recommended daily dose should not be exceeded (see section 4.2).
Insulin sensitivity
Somatropin may reduce insulin sensitivity. For patients with diabetes mellitus, the insulin dose may require adjustment after somatropin therapy is instituted. Patients with diabetes, glucose intolerance, or additional risk factors for diabetes should be monitored closely during somatropin therapy.
Thyroid function
Growth hormone increases the extrathyroidal conversion of T4 to T3 which may result in a reduction in serum T4 and an increase in serum T3 concentrations. Whereas the peripheral thyroid hormone levels have remained within the reference ranges in the majority of healthy subjects, hypothyroidism theoretically may develop in subjects with subclinical hypothyroidism. Consequently, monitoring of thyroid function should therefore be conducted in all patients. In patients with hypopituitarism on standard replacement therapy, the potential effect of growth hormone treatment on thyroid function must be closely monitored.
Hypoadrenalism
Introduction of somatropin treatment may result in inhibition of 11βHSD-1 and reduced serum cortisol concentrations. In patients treated with somatropin, previously undiagnosed central (secondary) hypoadrenalism may be unmasked and glucocorticoid replacement may be required. In addition, patients treated with glucocorticoid replacement therapy for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses, following initiation of somatropin treatment (see section 4.5).
Use with oral oestrogen therapy
If a woman taking somatropin begins oral oestrogen therapy, the dose of somatropin may need to be increased to maintain the serum IGF-1 levels within the normal age-appropriate range. Conversely, if a woman on somatropin discontinues oral oestrogen therapy, the dose of somatropin may need to be reduced to avoid excess of growth hormone and/or side effects (see section 4.5).
In growth hormone deficiency secondary to treatment of malignant disease, it is recommended to pay attention to signs of relapse of the malignancy. In childhood cancer survivors, an increased risk of a second neoplasm has been reported in patients treated with somatropin after their first neoplasm. Intracranial tumours, in particular meningiomas, in patients treated with radiation to the head for their first neoplasm, were the most common of these second neoplasms.
In patients with endocrine disorders, including growth hormone deficiency, slipped epiphyses of the hip may occur more frequently than in the general population. Children limping during treatment with somatropin, should be examined clinically.
Benign intracranial hypertension
In case of severe or recurrent headache, visual problems, nausea and/or vomiting, a funduscopy for papilloedema is recommended. If papilloedema is confirmed, a diagnosis of benign intracranial hypertension should be considered and, if appropriate, the growth hormone treatment should be discontinued. At present there is insufficient evidence to give specific advice on the continuation of growth hormone treatment in patients with resolved intracranial hypertension. If growth hormone treatment is restarted, careful monitoring for symptoms of intracranial hypertension is necessary.
Leukaemia
Leukaemia has been reported in a small number of growth hormone deficiency patients, some of whom have been treated with somatropin. However, there is no evidence that leukaemia incidence is increased in growth hormone recipients without predisposition factors.
Antibodies
As with all somatropin containing products, a small percentage of patients may develop antibodies to GENOTROPIN. GENOTROPIN has given rise to the formation of antibodies in approximately 1% of patients. The binding capacity of these antibodies is low and there is no effect on growth rate. Testing for antibodies to somatropin should be carried out in any patient with otherwise unexplained lack of response.
Elderly patients
Experience in patients above 80 years is limited. Elderly patients may be more sensitive to the action of GENOTROPIN, and therefore may be more prone to develop adverse reactions.
Acute critical illness
The effects of GENOTROPIN on recovery were studied in two placebo controlled trials involving 522 critically ill adult patients suffering complications following open heart surgery, abdominal surgery, multiple accidental trauma or acute respiratory failure. Mortality was higher in patients treated with 5.3 or 8 mg GENOTROPIN daily compared to patients receiving placebo, 42% vs. 19%. Based on this information, these types of patients should not be treated with GENOTROPIN. As there is no information available on the safety of growth hormone substitution therapy in acutely critically ill patients, the benefits of continued treatment in this situation should be weighed against the potential risks involved.
In all patients developing other or similar acute critical illness, the possible benefit of treatment with Genotropin must be weighed against the potential risk involved.
Pancreatitis
Although rare, pancreatitis should be considered in somatropin-treated patients, especially children who develop abdominal pain.
Prader-Willi syndrome
In patients with Prader-Willi syndrome, treatment should always be in combination with a calorie-restricted diet.
There have been reports of fatalities associated with the use of growth hormone in pediatric patients with Prader-Willi syndrome who had one or more of the following risk factors: severe obesity (those patients exceeding a weight/height of 200 %), history of respiratory impairment or sleep apnoea, or unidentified respiratory infection. Patients with one or more of these factors may be at increased risk.
Before initiation of treatment with somatropin in patients with Prader-Willi syndrome, signs for upper airway obstruction, sleep apnoea, or respiratory infections should be assessed.
If during the evaluation of upper airway obstruction, pathological findings are observed, the child should be referred to an Ear, nose and throat (ENT) specialist for treatment and resolution of the respiratory disorder prior to initiating growth hormone treatment.
Sleep apnoea should be assessed before onset of growth hormone treatment by recognised methods such as polysomnography or overnight oxymetry, and monitored if sleep apnoea is suspected.
If during treatment with somatropin patients show signs of upper airway obstruction (including onset of or increased snoring), treatment should be interrupted, and a new ENT assessment performed.
All patients with Prader-Willi syndrome should be monitored if sleep apnoea is suspected.
Patients should be monitored for signs of respiratory infections, which should be diagnosed as early as possible and treated aggressively.
All patients with Prader-Willi syndrome should also have effective weight control before and during growth hormone treatment.
Scoliosis is common in patients with Prader-Willi syndrome. Scoliosis may progress in any child during rapid growth. Signs of scoliosis should be monitored during treatment.
Experience with prolonged treatment in adults and in patients with Prader-Willi syndrome is limited.
Small for gestational age
In short children born SGA other medical reasons or treatments that could explain growth disturbance should be ruled out before starting treatment.
In SGA children it is recommended to measure fasting insulin and blood glucose before start of treatment and annually thereafter. In patients with increased risk for diabetes mellitus (e.g. familial history of diabetes, obesity, severe insulin resistance, acanthosis nigricans) oral glucose tolerance testing (OGTT) should be performed. If overt diabetes occurs, growth hormone should not be administered.
In SGA children it is recommended to measure the IGF-I level before start of treatment and twice a year thereafter. If on repeated measurements IGF-I levels exceed +2 SD compared to references for age and pubertal status, the IGF-I / IGFBP-3 ratio could be taken into account to consider dose adjustment.
Experience in initiating treatment in SGA patients near onset of puberty is limited. It is therefore not recommended to initiate treatment near onset of puberty. Experience in patients with Silver-Russell syndrome is limited.
Some of the height gain obtained with treating short children born SGA with growth hormone may be lost if treatment is stopped before final height is reached.
Chronic renal insufficiency
In chronic renal insufficiency, renal function should be below 50 percent of normal before institution of therapy. To verify growth disturbance, growth should be followed for a year preceding institution of therapy. During this period, conservative treatment for renal insufficiency (which includes control of acidosis, hyperparathyroidism and nutritional status) should have been established and should be maintained during treatment. The treatment should be discontinued at renal transplantation.
To date, no data on final height in patients with chronic renal insufficiency treated with Genotropin are available.
Sodium content
This medicinal product contains less than 1 mmol sodium (23 mg) per dose. Patients on low sodium diets can be informed that this medicinal product is essentially 'sodium free'.
Concomitant treatment with glucocorticoids inhibits the growth-promoting effects of somatropin containing products. Patients with Adrenocorticotropic hormone (ACTH) deficiency should have their glucocorticoid replacement therapy carefully adjusted to avoid any inhibitory effect on growth. Therefore, patients treated with glucocorticoids should have their growth monitored carefully to assess the potential impact of glucocorticoid treatment on growth.
Growth hormone decreases the conversion of cortisone to cortisol and may unmask previously undiscovered central hypoadrenalism or render low glucocorticoid replacement doses ineffective (see section 4.4).
Data from an interaction study performed in growth hormone deficient adults, suggests that somatropin administration may increase the clearance of compounds known to be metabolised by cytochrome P450 isoenzymes. The clearance of compounds metabolised by cytochrome P 450 3A4 (e.g. sex steroids, corticosteroids, anticonvulsants and ciclosporin) may be especially increased resulting in lower plasma levels of these compounds. The clinical significance of this is unknown.
Also see section 4.4 for statements regarding diabetes mellitus and thyroid disorder.
In women on oral oestrogen replacement, a higher dose of growth hormone may be required to achieve the treatment goal (see section 4.4).
Pregnancy
Animal studies are insufficient with regard to effects on pregnancy, embryofoetal development, parturition or postnatal development (see section 5.3). No clinical studies on exposed pregnancies are available. Therefore, somatropin containing products are not recommended during pregnancy and in women of childbearing potential not using contraception.
Breast-feeding
There have been no clinical studies conducted with somatropin containing products in breast-feeding women. It is not known whether somatropin is excreted in human milk, but absorption of intact protein from the gastrointestinal tract of the infant is extremely unlikely. Therefore caution should be exercised when somatropin containing products are administered to breast-feeding women.
GENOTROPIN has no influence on the ability to drive and use machines.
Patients with growth hormone deficiency are characterized by extracellular volume deficit. When treatment with somatropin is started this deficit is rapidly corrected. In adult patients adverse effects related to fluid retention, such as oedema peripheral, face oedema, musculoskeletal stiffness, arthralgia, myalgia and paraesthesia are common. In general these adverse effects are mild to moderate, arise within the first months of treatment and subside spontaneously or with dose-reduction.
The incidence of these adverse effects is related to the administered dose, the age of patients, and possibly inversely related to the age of patients at the onset of growth hormone deficiency. In children such adverse effects are uncommon.
Genotropin has given rise to the formation of antibodies in approximately 1 % of the patients. The binding capacity of these antibodies has been low and no clinical changes have been associated with their formation, see section 4.4.
Tabulated list of adverse reactions
Table 1 shows the adverse reactions ranked under headings of System Organ Class and frequency for children and adults, using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data)
Table 1: Tabulated list of adverse reactions
System organ class
Very common
(≥1/10)
Common
(≥1/100 to <1/10)
Uncommon
(≥1/1,000 to <1/100)
Rare
(≥1/10,000 to <1/1000)
Very rare
(<1/10,000)
Not known
(cannot be estimated from available data)
Neoplasms benign, malignant, and unspecified (including cysts and polyps)
(Children) Leukaemia†
Metabolism and nutrition disorders
(Adults and Children) Type 2 diabetes mellitus
Nervous system disorders
(Adults) Paraesthesia*
(Adults) Carpal tunnel syndrome
(Children) Benign intracranial hypertension
(Children) Paraesthesia*
(Adults) Benign intracranial hypertension
(Adults and Children) Headache
Skin and subcutaneous tissue disorders
(Children) Rash**, Pruritus**, Urticaria**
(Adults) Rash**, Pruritus**, Urticaria**
Musculoskeletal and connective tissue disorders
(Adults) Arthralgia*
(Adults) Myalgia*
(Adults) Musculoskeletal stiffness*
(Children) Arthralgia*
(Children) Myalgia*
(Children) Musculoskeletal stiffness*
Reproductive system and breast disorders
(Adults and Children) Gynaecomastia
General disorders and administration site conditions
(Adults) Oedema peripheral *
(Children) Injection-site reaction$
(Children) Oedema peripheral*
(Adults and Children) Face oedema*
(Adults) Injection-site reaction$
Investigations
(Adults and Children) Blood cortisol decreased‡
* In general, these adverse effects are mild to moderate, arise within the first months of treatment, and subside spontaneously or with dose-reduction. The incidence of these adverse effects is related to the administered dose, the age of the patients, and possibly inversely related to the age of the patients at the onset of growth hormone deficiency.
** Adverse Drug Reactions (ADR) identified post-marketing.
$ Transient injection site reactions in children have been reported.
‡ Clinical significance is unknown
† Reported in growth hormone deficient children treated with somatropin, but the incidence appears to be similar to that in children without growth hormone deficiency.
Reduced serum cortisol levels
Somatropin has been reported to reduce serum cortisol levels, possibly by affecting carrier proteins or by increased hepatic clearance. The clinical relevance of these findings may be limited. Nevertheless, corticosteroid replacement therapy should be optimised before initiation of GENOTROPIN therapy.
Prader-Willi syndrome
In the post-marketing experience rare cases of sudden death have been reported in patients affected by Prader-Willi syndrome treated with somatropin, although no causal relationship has been demonstrated.
Leukaemia
Cases of leukaemia have been reported in children with a GH deficiency, some of whom were treated with somatropin and included in the post-marketing experience. However, there is no evidence of an increased risk of leukaemia without predisposition factors, such as radiation to the brain or head.
Slipped capital femoral epiphysis and Legg-Calve-Perthes disease
Slipped capital femoral epiphysis and Legg-Calve-Perthes disease have been reported in children treated with GH. Slipped capital femoral epiphysis occurs more frequently in case of endocrine disorders and Legg-Calve-Perthes is more frequent in case of short stature. But, it is unknown if these 2 pathologies are more frequent or not while treated with somatropin. Their diagnosis should be considered in a child with a discomfort or pain in the hip or knee.
Other adverse drug reactions
Other adverse drug reactions may be considered somatropin class effects, such as possible hyperglycaemia caused by decreased insulin sensitivity, decreased free thyroxin level and benign intra-cranial hypertension.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Symptoms
Acute overdosage could lead initially to hypoglycaemia and subsequently to hyperglycaemia.
Long-term overdosage could result in signs and symptoms consistent with the known effects of human growth hormone excess.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Genotropin 5.3mg powder and solvent for solution for injection. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.